Gene transfer to muscle using herpes simplex virus-based vectors

Neuromuscular Disorders

Volumn 7, Issue 5, 1997, Pages 299-313

  Huard, Johnny ^a   Krisky, David ^b   Oligino, Thomas ^b   Marconi, Peggy ^b   Day, Charles S ^a   Watkins, Simon C ^c   Glorioso, Joseph C ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Duchenne muscular dystrophy; Gene therapy; Herpes simplex virus

Indexed keywords

DYSTROPHIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CYTOTOXICITY; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; MOUSE; MUSCLE CELL; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; VIRUS MUTANT;

ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUSCLES; SIMPLEXVIRUS;

EID: 0030824160     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(97)00054-0     Document Type: Article

References (101)

1. Hoffman EP, Brown J, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
2. Arahata K, Ishiura S, Ishiguro T, et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 1988;333:861-863.
3. Sugita H, Arahata K, Ishiguro T, et al. Negative immunostaining of Duchenne muscular dystrophy (DMD) and mdx muscle surface membrane with antibody against synthetic peptide fragment predicted from DMD cDNA. Proc Jpn Acad 1988;64:37-39.
4. Zubryzcka-Gaarn EE, Bulman DE, et al. The Duchenne muscular dystrophy gene is localised in the sarcolemma of human skeletal muscle. Nature 1988;333:466-469.
5. Menke A, Jokush H. Decreased osmotic stability of dystrophin less muscle cells from the mdx mice. Nature 1991;349:69-71.
6. Bonilla ECE, Samitt AF, Miranda AP, et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988;54:447-452.
7. Watkins SC, Hoffman EP, Slayter HS, Kunkel LM. Immunoelectron microscopic localization of dystrophin in myofibers. Nature 1988;333:863-866.
8. Bulfield G, Siller WG, Wright PAL, Moore KJ. X-chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81:1189-1192.
9. Sincinsky P, Geng Y, Ryder-Cook A, Barnard E, Darlinson M, Barnard P. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580.
10. Partridge TA. Myoblast transfer: a possible therapy for inherited myopathies. Muscle Nerve 1991;14:197-212.
11. Law PK, Goodwin TG, Li HJ. Histoincmpatible myoblast injection improves muscle structure and function of dystrophic mice. Transplant Proc 1988a;20:1014-1019.
12. Alamedine HS, Dehaupas M, Fardeau M. Regeneration of skeletal muscle fiber from autologous satellite cells multiplied in vitro. Muscle Nerve 1989;12:544-555.
13. Huard J, Labrecque C, Dansereau G, Robitaille L, Tremblay JP. Dystrophin expression in myotubes formed by the fusion of normal and dystrophic myoblasts. Muscle Nerve 1991;14:178-182.
14. Karpati G, Pouliot Y, Zubrzycka-Gaarn EE, et al. Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am J Pathol 1989;135:27-32.
15. Morgan JE, Hoffman EP, Partridge TA. Normal myogenic cells from newborn mice restore normal histology to degenerating muscle of the mdx mouse. J Cell Biol 1990;111:2437-2449.
16. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibers from dystrophin negative to positive by injection of normal myoblasts. Nature 1989;337:176-179.
17. Gussoni E, Pavlath PK, Lanctot AM, et al. Normal dystrophin transcripts detected in DMD patients after myoblast transplantation. Nature 1992;356:435-438.
18. Huard J, Bouchard JP, Roy R, et al. Human myoblast transplantation: preliminary results of four cases. Muscle Nerve 1992A;15:550-560.
19. Karpati G, Ajdukovic D, Arnold D, et al. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993;34:8-17.
20. Tremblay JP, Malouin F, Roy R, et al. Results of a blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993;2:99-112.
21. Law PK, Goodwin TG, Fang Q, et al. Pioneering development of myoblast transfer therapy. In: Angelini C, Darrieli GA, Fontanan D, eds. Muscular Dystrophy Research Excerpta Medica. International Congress Series 934. NewYork: Elsevier, 1991;109-116.
22. Huard J, Roy R, Bouchard JP, Malouin F, Richards CL, Tremblay JP. Human myoblast transplantation between immunohistocompatible donnors and recipients produces immune reactions. Transplant Proc 1992B;6:3049-3051.
23. Vilquin JT, Wagner E, Kinoshita I, Roy R, Tremblay JP. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 1995;131:975-988.
24. Huard J, Guerette B, Verreault S, Tremblay G, Roy R, Lille S, Tremblay JP. Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection. Muscle Nerve 1994A;17:224-234.
25. Huard J, Verreault S, Roy R, Tremblay M, Tremblay JP. High efficiency of muscle regeneration following human myoblast clone transplantation in SCID mice. J Clin Invest 1994B;93:586-599.
26. Kinoshita I, Vilquin JT, Guerette B, Asselin I, Roy R, Tremblay JP. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 1994;17:1407-1415.
27. Huard J, Acsadi G, Jani A, Massie B, Karpati G. Gene transfer into skeletal muscles by isogenic myoblasts. Hum Gene Ther 1994C;5:949-958.
28. Salvatori G, Ferrari G, Messogiorno A, et al. Retroviral vector-mediated gene transfer into human primary myogenic cells lead to expression in muscle fibers in vivo. Hum Gene Ther 1993;4:713-723.
29. Acsadi G, Dickson G, Love DR, et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991;352:815-818.
30. Katsumi A, Emi N, Abe A, Hasegawa Y, Ito M, Saito H. Humoral and cellular immunity to an encoded protein induced by direct DNA injection. Hum Gene Ther 1994;5:1335-1339.
31. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992;1:363-369.
32. Dunckley MG, Davies KE, Walsh FS, Morris GE, Dickson G. Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro. FEBS Lett 1992;296:128-134.
33. Acsadi G, Jani A, Huard J, et al. Cultured human myoblasts and myotubes show markedly different transducibility by replication defective adenovirus recombinant. Gene Ther 1994;1:338-340.
34. Quantin B, Perricaudet LD, Tajbakhsh S, Mandell JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992;89:2581-2584.
35. Ragot T, Vincent M, Chafey P, et al. Efficient adenovirus mediated gene transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993;361:647-650.
36. Vincent M, Ragot T, Gilgenkrantz H, et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993;5:130-134.
37. Acsadi G, Jani A, Massie B, et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells at different maturity. Hum Mol Genet 1994;3:579-584.
38. Smith TG, Mehaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993;5:397-402.
39. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2A in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-369.
40. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
41. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenovirus defective in E2A. Hum Gene Ther 1994A;5:1217-1229.
42. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory responses in mouse liver. Proc Natl Acad Sci USA 1994B;91:6196-6200.
43. Gage PJ, Sauer B, Levine M, Glorioso JC. A cell free recombination system for site specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J Virol 1992;66:5509-5515.
44. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985A;56:558-570.
45. Sanes JR, Rubenstein JLR, Nicolas JF. Use of a recombination retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J 1986;5:5133-5142.
46. Roizman B, Furlong D. The Replication of Herpes Viruses, Vol. 3. New York: Plenum Press, 1974.
47. Campadelli G, Brandimarti R, Lazzaro CD, Ward P, Roizman B, Torrisi M. Fragmentation and dispersal of Golgi proteins and redistribution of glycoproteins and glycolipids processed through Golgi following infection with herpes simplex virus 1. Proc Natl Acad Sci USA 1993;90:2798-2802.
48. Johnson D, Spear P. Monensin inhibits the processing of herpes simplex virus glycoproteins, their transport to the cell surface, and the egress of virions from infected cells. J Virol 1982;43:1102-1112.
49. Spear P. Membrane fusion induced by herpes simplex virus. In: Bentz J, ed. Viral Fusion Mechanisms. Boca Raton, FL: CRC Press, 1993:201-232.
50. Hammerschmidt W, Sugden B. Genetic analysis of immortalization functions of Epstein-Barr virus in human B lymphocytes. Nature 1989;340:393-397.
51. Herold B, WuDunn D, Soltys N, Spear P. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol 1991;65:1090-1098.
52. Shieh M-T, Spear P. Herpes virus-induced cell fusion that is dependent on cell surface heparin sulfate on soluble heparin. J Virol 1994;68:1224-1228.
53. Wudunn D, Spear P. Initial interaction of herpes simplex virus with cells is binding to heparin sulfate. J Virol 1989;63:52-58.
54. Ligas M, Johnson D. A herpes simplex virus mutant in which glycoprotein D sequences are replaced by β-galactosidase sequences binds to but is unable to penetrate into cells. J Virol 1988;62:1486-1494.
55. Johnson D, Burke R, Gregory T. Soluble forms of Herplex simplex virus glycoprotein D bind to limited number of cell surface receptors and inhibit virus entry into cells. J Virol 1990;64:2569-2576.
56. Cai W, Person S, Warner S, Zhou J, Glorioso J. Linker insertion non-sense and restriction-site deletion mutations of the gB glycoprotein gene of herpes simplex virus type 1. J Virol 1987;61:714-721.
57. Desai P, Schaffer P, Minson A. Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes-simplex virus type 1: evidence that gH is essential for virion infectivity. J Gen Virol 1988;69:1147-1156.
58. Hutchinson L, Browne H, Wargent V, et al. A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J Virol 1992;6:2240-2250.
59. Roop C, Hutchinson L, Johnson D. A mutant herpes simplex virus type 1 unable to express glycoprotein 1 cannot enter cells, and its particles lack glycoprotein H. J Virol 1993;67:2285-2297.
60. Cai W, Gu B, Person S. Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol 1988;62:2596-2604.
61. Navarro D, Paz P, Pereira L. Domains of herpes simplex virus 1 glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion. Virology 1992;186:99-112.
62. Furlong D, H. Swift, Roizman B. Arrangement of herpes-virus deoxyribonucleic acid in the core. J Virol 1972;10:1071-1074.
63. Gibson W, Roizman B. Compartmentalization of spermine and spermidine in the herpes simplex virion. Proc Natl Acad Sci USA 1971;68:2818-2821.
64. Honess R, Roizman B. Regulation of herpes simplex virus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974;14:8-19.
65. Gerster T, Roeder R. A herpes virus trans-activating protein interacts with transcription factor OTF-1 and other cellular proteins. Proc Natl Acad Sci USA 1988;85:6347-6351.
66. Katan M, Haigh A, Verrijzer C, Vliet PVD, O'Hare P. Characterization of a cellular factor which interacts functionally with Oct-1 in the assembly of a multicomponent transcription complex. Nucleic Acids Res 1990;18:6871-6880.
67. Kristie T, Sharp P. Purification of the cellular C1 factor required for the stable recognition of the Oct-1 homeodomain by herpes simplex virus a-trans-induction factor (VP16). J Biol Chem 1993;268:6525-6534.
68. O'Hare P, Goding C. Herpes simplex virus regulatory elements and the immunoglobulin octameter domain bind a common factor and are both targets for virion trans-activation. Cell 1988a;52:435-445.
69. Preston C, Frame M, Campbell M. A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell 1988;52:425-434.
70. Werstuck G, Capone J. An unusual cellular factor potentiates protein-DNA complex assembly Oct-1 and Vmw65. J Biol Chem 1993;268:1272-1278.
71. Wilson A, LaMarco K, Peterson M, Herr W. The VP16 accessory protein HCF is a family of polypeptides processed from a large precursor protein. Cell 1993;74:115-125.
72. Desai P, Ramakrishnan R, Lin ZW, Ozak B, Glorioso JC, Levine M. The RR1 gene of herpes simplex virus type 1 is uniquely transactivated by ICPO during infection. J Virol 1993;67:6125-6135.
73. DeLuca NA, Schaffer PA. Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4. Mol Cell Biol 1985b;5:1997-2008.
74. Sacks W, Greene C, Aschman D, Schaffer P. Herpes simplex virus type 1 ICP27 is essential regulatory protein. J Virol 1985;55:796-805.
75. Dixon RAF, Schaffer PA. Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J Virol 1980;36:189-203.
76. Preston C. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 1979a;29:275-84.
77. Watson R, Clements J. A herpes simplex virus type 1 function continuously required for early and late virus RNA synthesis. Nature 1980;285:329-30.
78. Holland LE, Anderson KP, Shipman C, Wagner EK. Viral DNA synthesis is required for efficient expression of specific herpes simplex virus type 1 mRNA. Virology 1980;101:10-24.
79. Mavromara-Nazos P, Roizman B. Activation of herpes simplex virus 1 γ2 genes by viral DNA replication. Virology 1987;161:593-598.
80. Brown C, Nakamura M, Mosca J, Hayward G, Straus S, Perera L. Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3′ ends of labile mRNA. J Virol 1995;69:7187-7195.
81. McGregor F, Phelan A, Dunlop J, Clements J. Regulation of herplex simplex virus poly(A) site usage and the action of immediate-early protein IE63 in the early-late swith. J Virol 1996;70:1931-1940.
82. Sandri-Goldin R, Hibbard M. The herpes simplex virus type 1 regulatory protein ICP27 co-immunoprecipitates with anti-sm antiserum, and the C terminus appears to be required for this interaction. J Virol 1996;70:108-118.
83. Sandri-Goldin R, Hibbard M, Hardwicke M. The C-terminal represser region of herpes simplex virus type 1 ICP27 is required for the redistribution of small nuclear ribonucleoprotein particles and splicing factor SC25; however, these alterations are not sufficient to inhibit host cell splicing. J Virol 1996;69:6063-6076.
84. Smith IL, Hardwicke MA, Sandri-Goldin RM. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 1992;186:74-86.
85. Rice S, Long M, Lam V, Spencer C. RNA polymerase II is aberrantly phosphorylated and localised to viral replication compartments following herpes simplex virus infection. J Virol 1994;68:988-1001.
86. York I, Roo C, Andrews D, Riddell S, Graham F, Johnson D. A cytosolic herpes simplex virus protein inhibits antigen presentation to CDS + T lymphocytes. Cell 1994;77:525-35.
87. Challberg M. A method of identifying the viral genes required for herpes virus DNA replication. Proc Natl Acad Sci USA 1986;83:9094-9098.
88. Jacob R, Morse L, Roizman B. Anatomy of herpes simplex virus DNA XII. Accumulation of head-to-tail concatomers in nuclei of infected cells and their rule in the generation of the four isomeric arrangements of viral DNA. J Virol 1979;29:448-57.
89. Skaliter R, Makhov A, Griffith J, Lehman I. Rolling circle DNA replication by extracts of herpes simplex virus type 1-infected human cells. J Virol 1996;70:1132-1136.
90. Davison A, Wilkie N. Inversion of the two segments of the herpes simplex virus genome in intertypic recombinants. J Gen Virol 1983;64:1-18.
91. Mocarski E, Roizman B. Structure and role of the herpes simplex virus DNA termini in inversion, circularization and generation of virion DNA. Cell 1982;31:89-97.
92. Deiss L, Chou J, Frenkel N. Functional domains within the a sequence involved in the cleavage-packaging of herpes simplex virus DNA. J Virol 1986a;57:605-618.
93. Frenkel N, Locker H, Batterson W, Hayward G, Roizman B. Anatomy of herpes simplex DNA. VI. Defective DNA originates from the S component. J Virol 1976;20:527-531.
94. Huard J, Goins B, Glorioso JC. Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Ther 1995B;2:1-9.
95. Huard J, Feero WG, Watkins SC, Hoffman EP, Rosenblatt DJ, Glorioso JC. The basal lamina is a physical barrier to HSV mediated gene delivery to mature muscle fibers. J Virol 1996;70:8117-8123.
96. Huard J, Akkaraju G, Watkins SC, Pike-Cavacoli M, Glorioso J. LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type-1 mutant vector. Hum Gene Ther, 1997;8:439-452.
97. Johnson P, Miyanohara A, Levine F, Cahill T, Friedmann T. Cytotoxicity of a replication-defective mutant herpes simplex virus type 1. J Virol 1992a;66:2952-65.
98. Johnson P, Wang M, Friedman T. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the viron host shut-off function. J Virol 1994;68:6347-62.
99. Kwong AD, Kruper JA, Frenkel N. Herpes simplex virus virion host shut-off function. J Virol 1988;62:912-921.
100. Oroskar A, Read G. Control of mRNA stability by the virion host shut-off function of herpes simplex virus. J Virol 1989;63:1897-1906.
101. Read GS, Frenkel N. Herpes simplex virus mutants defective in the virion-associated shut-off of host polypeptide synthesis and exhibiting abnormal synthesis of a (immediate early) viral polypeptides. J Virol 1983;46:498-512.